Search

Your search keyword '"Avvisati, G."' showing total 359 results
Start Over Author "Avvisati, G." Publication Type Academic Journals
359 results on '"Avvisati, G."'

1. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

Author

Annibali, O., Petrucci, M.T., Santini, D., Bongarzoni, V., Russano, M., Pisani, F., Venditti, O., Pantano, F., Rago, A., Siniscalchi, A., Cerchiara, E., Franceschini, L., De Rosa, L., Mariani, M., Andriani, S, Cudillo, L., Garcia, M., Cantonetti, M., Mohamed, S., Anaclerico, B., Caravita, T., Stocchi, F., Cimino, G., Gumenyuk, S., Vozella, F., and Avvisati, G.

Published
2021
Full Text
View/download PDF

5. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network

Author

Marchesi, F., Mengarelli, A., Giannotti, F., Tendas, A., Anaclerico, B., Porrini, R., Picardi, A., Cerchiara, E., Dentamaro, T., Chierichini, A., Romeo, A., Cudillo, L., Montefusco, E., Tirindelli, M. C., De Fabritiis, P., Annino, L., Petti, M. C., Monarca, B., Arcese, W., and Avvisati, G.

Published
2014
Full Text
View/download PDF

14. Rome Transplant Network, a metropolitan haematopoietic stem cell transplant programme: P824

Author

Arcese, W, Picardi, A., Mauroni, M. R., Adorno, G., Lanti, A., Locatelli, F., Caniglia, M., Ciscato, C., Isacchi, G., Zinno, F., De Fabritiis, P., Dentamaro, T., Delogu, S., Avvisati, G., Tirindelli, M. C., Mazzaroni, M., Petti, C., Mengarelli, A., Pignatelli, A., Monarca, B., Montefusco, E., Grigora, D., Annino, L., Chierichini, A., Pilozzi, V., Angelini, S., Mangione, I., Papa, C., and Miccichè, S.

Published
2011

35. Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia.

Author

Tshilolo, L., Summa, V., Gregorj, C., Kinsiama, C., Bazeboso, J. A., Avvisati, G., and Labie, D.

Abstract

High HbF levels and F cells are correlated with reduced morbidity and mortality in sickle cell disease (SCD). This paper was designed to determine the HbF and F cells levels in Congolese sickle cell anemia (SCA) patients in order to determine their impact on the expression of SCD. Population and Method. HbF levels were measured in 89 SCA patients (mean age 11.4 yrs) using a standard HPLC method. F cell quantitation was done in a second group of SCA patients (n = 42, mean age 8.9 yrs) and compared with a control group (n = 47, mean age 5 yrs). F cells were quantified by a cytofluorometric system (MoAb-HbF-FITC; cut off at 0.5%). Results. The mean value of HbF was 7.2%±5.0 with heterogeneous distribution, most patients (76%) having HbF < 8%. Mean values of F-cells in SCA patients and control group were 5.4%±7.6 (median: 2.19% ; range 0,0-30,3%) and 0.5%±1.6 (median 0.0, range 0-5.18), respectively. SCA patients with F cells >4.5% developed less painful crisis and had higher percentage of reticulocytes. Conclusion. Congolese SCA patients displayed low levels of HbF and F-cells that contribute to the severity of SCD. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

36. Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia.

Author

Marchesi, F., Girardi, K., and Avvisati, G.

Subjects
LYMPHOBLASTIC leukemia, B cells, LYMPHOCYTIC leukemia, CHROMOSOME abnormalities, LEUKEMIA, CLINICAL trials
Abstract

Translocation t(4;11)(q21;q23) leading to formation of MLL-AF4 fusion gene is found in about 10% of newly diagnosed B-cell acute lymphoblastic leukemia (ALL) in adult patients. Patients expressing this chromosomal aberration present typical biological, immunophenotypic, and clinical features. This form of leukemia is universally recognized as high-risk leukemia and treatment intensification with allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR) could be a valid option to improve prognosis, but data obtained from the literature are controversial. In this review, we briefly describe pathogenetic, clinical, and prognostic characteristics of adult t(4;11)(q21;q23)/MLL-AF4 positive ALL and provide a review of the clinical outcome reported by the most important cooperative groups worldwide. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

39. Treatment of elderly patients (=60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.

Author

Mandelli, F, Latagliata, R, Avvisati, G, Fazi, P, Rodeghiero, F, Leoni, F, Gobbi, M, Nobile, F, Gallo, E, Fanin, R, Amadori, S, Vignetti, M, Fioritoni, G, Ferrara, F, Peta, A, Giustolisi, R, Broccia, G, Petti, M C, and Lo-Coco, F

Subjects
LEUKEMIA, OLDER people
Abstract

In all, 134 elderly patients (median age 66 years, range 60-75 years) with newly diagnosed acute promyelocytic leukemia (APL) were enrolled in two successive protocols of the Italian multicenter group GIMEMA. All patients received an identical induction with all-trans retinoic acid and idarubicin; 116 (86%) entered complete remission (CR), two (2%) were resistant and 16 (12%) died during induction. After CR, 106 patients received further therapy whereas 10 did not, because of refusal (n = 5) or toxicity (n = 5). Consolidation consisted of three chemotherapy courses in the AIDA protocol (AIDA, 67 patients) or, since 1997, of an amended protocol including only the first cycle (amended AIDA, aAIDA, 39 patients). In the AIDA group, 43 patients (64%) completed consolidation, while seven (11%) and 17 (25%) patients were withdrawn after first and second courses, respectively; nine patients (13%) died in CR and 12 (18%) relapsed. In the aAIDA group, all patients received the assigned treatment; two patients (5%) died in CR and six (15%) relapsed. In the AIDA and aAIDA series, the 3-year overall and discase-free survival rates were 81 and 83% (P = NS), 73 and 72% (P = NS), respectively. We highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that, in APL of the elderly, less intensive postremission therapy allows significant reduction of severe treatment-related toxicity and may be equally effective. [ABSTRACT FROM AUTHOR]

Published
2003

43. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Author

Grandi, C., Regazzi, M.B., Spreafico, S., Russo, D., Grattoni, R., Iacona, I., Galieni, P., Sacchi, S., Rupoli, S., Visani, G., Maiolo, A.M., Lazzarino, M., Guerra, E., Avvisati, G., Liberati, A.M., Pelicci, P.G., and Dastoli, G.

Subjects
TRETINOIN, LEUKEMIA treatment, MYELOID leukemia, PHARMACOKINETICS
Abstract

Objective: This study investigated the pharmacokinetics of tretinoin during alternating cycles of 1 week of tretinoin treatment and 1 week drug-free in patients with Ph1+ chronic myelogenous leukaemia (CML) in the chronic phase. Patients: Eighteen patients with CML were treated with tretinoin 80 mg/m/day (in two divided doses) for 7 consecutive days every other week (one cycle = 1 week on/1 week off). Results: Body systemic exposure to tretinoin as determined by the area under the plasma concentration-time curve (AUC) decreased significantly during the first week of drug administration, from (mean ± SD) 678.3 ± 498.1 to 258.7 ± 272.4 µg/L·h. In about 40% of the patients the decline in plasma concentrations was ≥80%, while 17% of the population did not experience any decline. On day 7 of cycle 1, the mean apparent oral clearance (CL/F) was 2.6 times the corresponding value on day 1. After 1 week without tretinoin, the mean AUC on day 1 of cycle 2 was lower (down 15%) but not statistically different from the corresponding value observed on day 1 of cycle 1; 62% of patients showed an increase in the AUC, which was 40% higher than the corresponding value on day 7 of cycle 1. On day 1 of cycle 6, the AUC and CL/F of tretinoin during a dosage interval were not statistically different from those observed on day 1 of cycle 1 and cycle 2. On all occasions the peak plasma concentration (C) was strongly correlated to the corresponding AUC. No significant change in the time to observed C (t) and in the elimination half-life (t) was observed during the whole study. These results confirmed that the metabolism of tretinoin is rapidly up-regulated in CML patients, with significant declines in plasma drug exposure during the first week of drug administration. After tretinoin was discontinued, a return to the noninduced state followed a mean time-cycle similar to the induction. The strong decrease in the apparent oral drug clearance and the absence of significant variations in the drug half-life demonstrated that the presystemic extraction of tretinoin is the main cause of the marked decline in plasma drug exposure. Conclusion: The favourable pharmacokinetic profile of tretinoin obtained by an intermittent regimen, 1 week on/1 week off therapy (vs continuous administration), suggests that such a therapeutic schedule is the most appropriate for the assessment of clinical efficacy in those pathologies in which its use is suitable. [ABSTRACT FROM AUTHOR]

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results